August 23, 2007 — Zyvex Labs’ first company spinout, NanoMed Inc., is focused on nanotechnology for life sciences, and will pursue application of nanoparticle technologies for the development of research grade reagents and cutting-edge therapeutics. In addition, NanoMed will seek to license its collection of nanotechnology. The new company leverages Zyvex’s existing life science patents, proprietary methods, and core technologies.
“The application of Zyvex Performance Materials’ Kentera and other polymers for functionalizing carbon nanotubes will play an integral role in solidifying NanoMed’s portfolio of cutting-edge nanotechnologies as they relate to the biomedical sciences,” said Rob Burgess, Ph.D., NanoMed’s Co-Founder and Chairman of the Board. Burgess is former Vice President of Research & Development at Zyvex Instruments Gareth Hughes, PhD, former Grou;p Leader of Life Sciences at Zyvex Corp. is also a co-founder.